aHSP antibody (HRP)

Catalog No. ABIN1421062

Product Details anti-aHSP Antibody (HRP)

Target: aHSP (alpha Hemoglobin Stabilizing Protein (aHSP))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This aHSP antibody is conjugated to HRP

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Cross-Reactivity: Human

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human AHSP/ERAF

Isotype: IgG

Application Details

Application Notes: WB 1:300-5000
IHC-P 1:200-400

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Do NOT add Sodium Azide! Use of Sodium Azide will inhibit enzyme activity of horseradish peroxidase.

Storage: -20 °C

Storage Comment: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Expiry Date: 12 months

Target Details for aHSP

Target: aHSP (alpha Hemoglobin Stabilizing Protein (aHSP))

Alternative Name: AHSP (aHSP Products)

Synonyms: AHSP antibody, ERAF antibody, EDRF antibody, Eraf antibody, alpha hemoglobin stabilizing protein antibody, alpha-hemoglobin-stabilizing protein-like antibody, AHSP antibody, Ahsp antibody, LOC100620111 antibody

Background:

Synonyms: AHSP, AHSP_HUMAN, Alpha hemoglobin stabilizing protein, Alpha-hemoglobin-stabilizing protein, EDRF, ERAF, Erythroid associated factor, Erythroid dferentiation associated factor, Erythroid dferentiation related factor, Erythroid dferentiation-related factor, Erythroid-associated factor.

Background: Act as a chaperone to prevent the harmful aggregation of alpha-hemoglobin during normal erythroid cell development. Specifically protects free alpha-hemoglobin from precipitation. It is predicted to modulate pathological states of alpha-hemoglobin excess such as beta-thalassemia.